Trastuzumab beyond progression: a challenge to translational oncology?
Santoro
A
A
Oncology and Haematology Unit, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Gullo
G
G
Department of Oncology, St Vincent's University Hospital, Dublin, Ireland. Electronic address: g.gullo@svuh.ie.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008495:Medical Oncology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D057170:Translational Research, Biomedical; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab